Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

Gastroenterology

Volumn 119, Issue 3, 2000, Pages 631-638

  Lanza, Frank L ^a   Hunt, Richard H ^b   Thomson, Alan B R ^c   Provenza, J Mark ^d   Blank, Marion A ^e  

^a Houston Institute for Clinical Research   (United States)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Gastrointestinal Specialists   (Canada)

^e PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENDOSCOPY; ESOPHAGUS ULCER; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; TREATMENT OUTCOME; UNITED STATES;

EID: 0033851184     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.16517     Document Type: Article

References (39)

1. Bisphosphonates: Structure-activity relationships and therapeutic implications
2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial
3. Risedronate prevents bone loss in early postmenopausal women
4. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women a randomized trial
5. Risedronate therapy prevents corticosteroid-induced bone loss
6. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
7. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
8. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction
9. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
10. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases
11. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation
12. Pamidronate: An unrecognized problem in gastrointestinal tolerability
13. Esophagitis associated with the use of alendronate
14. Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate
15. Primary amino-bisphosphonates: A new class of gastrotoxic drugs - Comparison of alendronate and aspirin
16. Alendronate gastric ulcers
17. Effects of alendronate on gastric and duodenal mucosa
18. 2): Results of a randomized controlled trial
19. Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate
20. Nonclinical model for assessing gastric effects of bisphosphonates
21. Healing and relapse of severe peptic esophagitis after treatment with omeprazole
22. The analysis of several 2 x 2 contingency tables
23. The combination of alendronate and naproxen is synergistic regarding the production of gastric ulcers
24. No evidence of H. pylori-NSAID interaction in ulcer formation: Results of double-blind, placebo-controlled trials
25. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs
26. Nonsteroidal anti-inflammatory drug gastropathy
27. Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity
28. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
29. A randomized trial comparing the effect of rofecoxib, a cycooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
30. Rolling review: Upper gastrointestinal bleeding
31. Upper gastrointestinal tract hemorrhage
32. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
33. Alendronate induces gastric injury and delays ulcer healing in rodents
34. A gut feeling for alendronate
35. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
36. Drug-induced gastric ulcers are caused by more than just NSAIDs: Alendronate gastric ulcers
37. Silent peptic ulceration: Deadly silence or golden silence
38. Effect of bisphosphonates on the surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa